NCT07814742Not yet recruiting
Effectiveness of UrDiaCare
Effectiveness of UrDiaCare: A Knowledge-Grounded Urdu Large Language Diabetes Management Application on Glycaemic Control Self Management Among Adults With Type 2 Diabetes in Pakistan: A Randomised Controlled Trial
Source: ClinicalTrials.gov · Last updated 21 Sept 2026
Brief summary (registry, in English)
The goal of this clinical trial is to learn if UrDiaCare, an Urdu-language diabetes support tool, can help adults with type 2 diabetes manage their Diabetes and improve blood sugar levels. The study will include adults aged 30 to 70 years with type 2 diabetes and higher-than-recommended blood sugar levels. The main question is whether UrDiaCare can lower HbA1c, a blood test that shows average blood sugar levels over the past few months, after four months. Researchers will compare UrDiaCare plus standard diabetes care with standard diabetes care plus a single Urdu educational pamphlet. UrDiaCare provides diabetes self-management education and support through WhatsApp/Android. It uses a fixed, health-professional-reviewed information library and does not provide diagnosis or prescribe treatment.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 406 (estimated)
- First submitted
- 4 Sept 2026
- Start date
- 15 Sept 2026
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- National University of Medical Sciences, Pakistan
- Diseases
- Type 2 diabetes
- NCT number
- NCT07814742
What you commit to
- Study type: Interventional
- Planned participants: 406
- From 15 Sept 2026 to the primary completion date, 31 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Current insulin therapy (to avoid confounding from differing self-management complexity)
Other illness
- Type 1, gestational, or secondary diabetes (e.g., steroid-induced, MODY)
- Severe, uncorrectable comorbidity likely to materially affect glycemic control or survival within 4 months (e.g., end-stage renal disease, active malignancy, liver failure)
- Significant cognitive impairment or psychiatric disorder precluding informed consent or technology use
- Participation in another diabetes clinical trial within the preceding 3 months
Other
- Insufficient Urdu reading proficiency, as the UrDiaCare interface is Urdu-script based
Who the study is looking for
- Adults aged 30-70 years with T2DM confirmed ≥ 6 months (clinical record) and HbA1c ≥ 7.5% at screening
- Currently prescribed oral antidiabetic medication(s) for ≥ 3 months
- Personal ownership and regular daily use of a functioning smartphone (Android/iOS)
- Able to read and understand Urdu
- Available for the full 4-month study period and willing to provide written informed consent -
Age in the registry: 30 years to 70 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| District Headquarter Hospital Coordinator of this site? Confirm its status | Gujranwala | Pakistan | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.